A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma - Trial NCT05683171
Access comprehensive clinical trial information for NCT05683171 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 1/2
Jun 30, 2023
Sep 30, 2027
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Summary
To find a recommended dose of valemetostat that can be given in combination with rituximab
 and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug
 combination will also be studied
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05683171
Non-Device Trial